Newsletter Subject

The Future of Biotech Is Here, and With It, Comes Opportunity

From

brownstoneresearch.com

Email Address

feedback@e.brownstoneresearch.com

Sent On

Sat, Mar 5, 2022 09:04 PM

Email Preheader Text

The Future of Biotech Is Here, and With It, Comes Opportunity By Jason Bodner, Editor, Outlier Inves

[The Bleeding Edge]( The Future of Biotech Is Here, and With It, Comes Opportunity [Jason] By Jason Bodner, Editor, Outlier Investor I read an article this weekend in a science journal about a man who was having an electroencephalogram (EEG) – a test to detect electrical activity in the brain – when he had a fatal heart attack. It was a tragedy, no doubt. But there was a silver lining – an unprecedented scientific observation that could feed future discoveries… See, the doctors monitored the man’s brain waves before, during, and after his death. I’m sure you’ve heard the phrase, “My life flashed before my eyes.” Well, his doctors found evidence to suggest there might be truth to the phenomenon of our lives “flashing” before our eyes. The brain activity picked up by the EEG machine right around the time of death resembled dreaming or recalling memories. And the data will help give scientists a greater understanding of how our brains store and recall information and how thought processes work. This article is just one example of the ways we’re gaining new insights into the human mind and body… which is feeding into many important areas of research. As we understand ourselves better, of course, we’ll be able to treat new diseases… cure conditions… and live longer and healthier lives than ever before. And this is quickly becoming an exciting field not only for researchers and scientists… but also for investors. Recommended Link [The Truth Behind the Global Chip Shortage]( [image]( GM and Toyota factories are shutting down... Mass shortages of electronics... Medical device production nearly halted... You may know a global computer chip shortage is happening. You may know something seems to be very wrong... But what you probably don't yet realize--what few so far have figured out... Is what's really causing it. And what happens next for investors. Now a former computer chip executive with over 20 years of experience is stepping forward to tell all... [Click Here to See His Urgent Warning.]( -- Companies on the Bleeding Edge Incredible companies are already standing out at the forefront of the biotech space. Neuralink, for example, has already successfully experimented with inserting microchips into the brains of animal subjects, which were then able to control computers with their minds. Cofounder Elon Musk eventually aims to use this technology to help people with paralysis. Today we are only at the first toddler steps of developing these kinds of technologies… Imagine decades into the future where we will be and what solutions might unfold! Another company working on the edge of science is Moderna (MRNA). It created a highly effective vaccine for COVID-19 using messenger RNA (mRNA). [Jeff Brown’s latest prediction…]( These vaccines teach our immune systems to react to proteins introduced with mRNA. The firm has several other mRNA vaccines and therapeutics currently in trials as well. Or look at Twist Bioscience (TWST). This company creates synthetic “control” versions of diseases like COVID-19 for safer research use. Twist also developed a viral test that detects COVID-19, MERS, SARS, and other strains of coronavirus, influenza, pneumonia, and more. Vertex Pharmaceuticals (VRTX), a firm I know well as an investor, just introduced a drug that helps 90% of cystic fibrosis patients breathe better and live better lives a couple of years ago. It’s now working on more treatments for six different diseases with clinical readouts expected this year. Then there’s 10X Genomics (TXG), which makes hardware and software tools for single-cell analysis. This enables scientists to identify changes at the cellular level of various types of tissues and create targeted treatments. There are so many more. Yet as investors, how do we know which of these companies – or the thousands of others out there – we should invest in? Recommended Link [Millionaire Trader Drops Bombshell… “The Only Trade You Will Ever Need”]( [image]( Silicon Valley trading millionaire says… “FORGET 99% of the Stock Market… Trade ONE Stock… ONCE Per Month – Over and Over Again!” He’s recommended REAL gains of 100%, 228%, and [373% in just 8-days – in any market condition.]( Leveraging a trading secret he’s used for years… helping over 171,000 regular people… It’s called: The [“One Stock Retirement”]( – a trading breakthrough to help anyone collect triple-digit profits regardless of trading experience, location, starting capital, or market condition. [Click here, it’s all revealed in this exclusive interview…]( -- How to Find the Best of Biotech We can make a strong case for investing in companies working on cutting-edge developments. Yes, some far-out things may never pan out… But others might. Some of these companies may become household names. For early investors in breakthrough companies, the sky is the limit. Those who get in early and see where the long-term opportunity goes can reap big rewards. In fact, the investments that succeed can far outweigh the ones that fail. Even better, my own AI system can help me point readers to the best of the best. My technology can pinpoint companies in a particular sector with the best fundamentals (such as strong earnings and low debt), technicals, and institutional buying patterns. This is especially important given the rough treatment the biotech sector as a whole has received over the past year. Outlier Investor, my research service, can help direct readers to stocks that have been unfairly punished and are primed to succeed in the coming year. [NFTs…“Buy, Buy, Buy”]( If you’d like to learn more about that, then I’d encourage you to [go right here for all the details](. But if you’re not ready to make that leap, then an ETF can help provide some broader exposure to this trend… One good option is the iShares Biotechnology ETF (IBB), which holds a basket of stocks focused on biotech innovation. Currently, it holds 375 stocks, including Moderna, Vertex, Twist Bioscience, 10X Genomics, and many more. IBB is the biggest biotech-focused ETF out there with more than $8 billion under management. “Big Money” investors like institutions and pension funds have liked IBB in the past. The green bars in the chart below show when IBB was bought in big volumes over the past year. Yet as you can see from the red sell indicators, IBB could be a bargain right now, as it has been sold off along with other growth assets during the recent market pullback: Recommended Link [Is America splitting in two…?]( [image]( What do Elon Musk, Joe Rogan, and Ben Shapiro have in common? They all fled “Commiefornia”. And they’re not alone… In total, 8.9 million Americans have relocated since the beginning of the pandemic. Some believe America is splitting in two… [But this is just the tip of the iceberg.]( There’s a much larger exodus ripping through the financial markets… You won’t read headlines about it in the mainstream press… You won’t find it on Google search… And you won’t see it trending on Twitter either. It has to do with a shocking new technological trend taking America by storm. And it’s creating a new class of millionaires, unlike anything we’ve seen before... while everyone else is left behind. If you have any kind of money in the markets.… [Click here for more details before it’s too late.]( -- What do buy and sell signals mean? My proprietary system tracks inflows of “Big Money” buyers and sellers. These are hedge funds, Wall Street firms, and other institutional players. When my system spots unusual levels of Big Money buying or selling, it triggers a buy signal (green) or sell signal (red). Sometimes, when we see Big Money piling in with lots of buy signals, we will try to jump on the trade and ride the wave up. As more and more institutional money flows into a stock (or ETF), it naturally pushes up the price in many cases. Other times, we may buy when Big Money is selling – especially if this is merely a pullback from lots of buying that has been taking place. This can give us a chance to enter a position on favorable terms and profit as Big Money returns to its primary buying trend. Investing in innovative biotech firms can bring big wins over time. And with an ETF like IBB, you can get exposure to lots of biotech innovations without too much concentration on any one company. Given the potential of this sector though, it’s worth building at least a small stake in the future of health care technology. The future is full of possibilities – just think of where one man’s life flashing before his eyes could lead us. To me, the application of innovative technology in the name of improving human health is a worthy long-term investment. Talk soon, Jason Bodner Editor, Outlier Investor --------------------------------------------------------------- Like what you’re reading? Send your thoughts to feedback@brownstoneresearch.com. --------------------------------------------------------------- In Case You Missed It… [** GOLD WARNING **]( If you own gold or gold stocks, read this warning immediately. An event in 2022 could have a massive impact on gold and other sectors, says the man who predicted the 2020 crash. “Move your money now.” The last time he issued a public warning like this, the market went on to see its biggest one-day drop ever. [Click here for the full details.]( [image]( --------------------------------------------------------------- Get Instant Access Click to read these free reports and automatically sign up for daily research. [The Ultimate Guide to Taking Back Your Privacy]( [The Trader’s Guide to Technical Analysis]( [How to Earn Free Bitcoin]( [Brownstone Research]( Brownstone Research 55 NE 5th Avenue, Delray Beach, FL 33483 [www.brownstoneresearch.com]( To ensure our emails continue reaching your inbox, please [add our email address]( to your address book. This editorial email containing advertisements was sent to {EMAIL} because you subscribed to this service. To stop receiving these emails, click [here](. Brownstone Research welcomes your feedback and questions. But please note: The law prohibits us from giving personalized advice. To contact Customer Service, call toll free Domestic/International: 1-888-512-0726, Mon–Fri, 9am–7pm ET, or email us [here](mailto:memberservices@brownstoneresearch.com). © 2022 Brownstone Research. All rights reserved. Any reproduction, copying, or redistribution of our content, in whole or in part, is prohibited without written permission from Brownstone Research. [Privacy Policy]( | [Terms of Use](

Marketing emails from brownstoneresearch.com

View More
Sent On

08/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Sent On

05/12/2024

Sent On

05/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.